Skip to main content

Table 1 (abstract P96). Baseline characteristics and interim analysis data of patients with TRAPS

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Baseline (N=16)

6 months (N=13)

12 months (N=10)

18 months (N=6)

Median duration of prior CAN therapy at baseline, years (min; max)

1.0 (0; 4)

1.0 (0; 4)

1.0 (0; 4)

1.5 (0; 2)

Number (%*) of patients in disease remission (physician assessment)

9 (60.0)

9 (81.8)

7 (77.8)

4 (80.0)

Physician Global Assessment, percentage of absent/mild-moderate/severe rating

40 / 53 / 0

82 / 9 / 0

44 / 44 / 11

80 / 20 / 0

Patients´ assessment of current disease activity; 0–10, median (min; max)

1.5 (0; 5)

1.0 (0; 4)

1.0 (0; 6)

0.0 (0; 3)

Patients´ assessment of current fatigue; 0–10, median (min; max)

2.0 (0; 8)

1.0 (0; 7)

2,5 (0; 8)

4.0 (0; 7)

Number (%*) of patients without impairment of social life by the disease

4 (50)

5 (63)

2 (33)

3 (60)

Number (%*) of patients with days absent from work/school during last 6 months

8 (50)

5 (39)

5 (56)

3 (50)

CRP, median (mg/dl)

0.1

0.1

0.1

0.0

SAA, median (mg/dl)

0.5

0.4

0.4

0.3

  1. CRP c-reactive protein, SAA serum amyloid A
  2. *Numbers/percentage do not sum up to N=16/13/10/6/100%, due to missing data in some patients